ArticleEJHaem2025
Secondary Malignancies Following CAR T-Cell Therapy for B-Cell Malignancies: A Retrospective Analysis.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Refuel and endure: improving metabolic fitness and efficacy in CAR-T therapy.Immuno-oncology technology · 2026Article
- Secondary Malignancies Following CAR T-Cell Therapy for B-Cell Malignancies: A Retrospective Analysis.EJHaem · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chimeric antigen receptor T-cell (CART) therapy has shown clinical efficacy in relapsed and refractory large B-cell malignancies. There is emerging data on the long-term complications including risk of secondary malignancies. We aimed to describe the incidence and characteristics of secondary malignancies following CART therapy. Methods: We performed a single-center retrospective analysis of a prospectively collected cohort of 87 patients who received CART therapy for relapsed/refractory B-cell malignancies between January 2020 and August 2023. Results: Seven patients (8.0%) developed a secondary malignancy, with a median age of 57 years (40-77) and mean time to onset of 16.9 months (3-34.5 months). Two patients were diagnosed with MDS and five with AML. Six patients had cytogenetic abnormalities at diagnosis of MDS/AML. Five patients received hypomethylating agents and two received an allogeneic stem cell transplant as treatment for their myeloid malignancy. Two patients were alive at 12 months after diagnosis of their myeloid malignancy. The 12-month cumulative incidence function (CIF) was 2.3% (95% CI, 0.4%-7.3%) and the 24-month CIF was 6.9% (95% CI, 2.4%-14.4%). Conclusion: Development of a secondary malignancy is a potential complication following CART therapy. Results of this single-center study should be confirmed with larger multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.